drug price legislation

In a new report, Evercore ISI analyst Terry Haines discussed the potential for some form of drug pricing legislation in the U.S. within the next two years. The SPDR S&P Biotech (ETF) (NYSE: XBI) is down 35.3 percent in the past six months since Democratic presidential front-runner Hillary...